Optimized Systematic Review Tool: Application to Candidate Biomarkers for the Diagnosis of Hepatocellular Carcinoma.

Autor:	U MRA; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom., Shen EY; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.; Department of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan., Cartlidge C; Harrogate District Hospital, Harrogate, United Kingdom., Alkhatib A; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.; National Liver Unit, Menoufiya University, Shbeen El Kom, Egypt., Thursz MR; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom., Waked I; National Liver Unit, Menoufiya University, Shbeen El Kom, Egypt., Gomaa AI; National Liver Unit, Menoufiya University, Shbeen El Kom, Egypt., Holmes E; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.; Health Futures Institute, Murdoch University, Perth WA, Australia., Sharma R; Department of Surgery and Cancer, Imperial College London, London, United Kingdom., Taylor-Robinson SD; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.
Jazyk:	angličtina
Zdroj:	Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2022 Jul 01; Vol. 31 (7), pp. 1261-1274.
DOI:	10.1158/1055-9965.EPI-21-0687
Abstrakt:	This review aims to develop an appropriate review tool for systematically collating metabolites that are dysregulated in disease and applies the method to identify novel diagnostic biomarkers for hepatocellular carcinoma (HCC). Studies that analyzed metabolites in blood or urine samples where HCC was compared with comparison groups (healthy, precirrhotic liver disease, cirrhosis) were eligible. Tumor tissue was included to help differentiate primary and secondary biomarkers. Searches were conducted on Medline and EMBASE. A bespoke "risk of bias" tool for metabolomic studies was developed adjusting for analytic quality. Discriminant metabolites for each sample type were ranked using a weighted score accounting for the direction and extent of change and the risk of bias of the reporting publication. A total of 84 eligible studies were included in the review (54 blood, 9 urine, and 15 tissue), with six studying multiple sample types. High-ranking metabolites, based on their weighted score, comprised energy metabolites, bile acids, acylcarnitines, and lysophosphocholines. This new review tool addresses an unmet need for incorporating quality of study design and analysis to overcome the gaps in standardization of reporting of metabolomic data. Validation studies, standardized study designs, and publications meeting minimal reporting standards are crucial for advancing the field beyond exploratory studies. (©2022 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu